文献速递治疗药物监测与药物基因组学特殊人群用药

重症监护中多替拉韦与肠内营养共给:治疗药物监测试例系列

Dolutegravir with enteral feeds in intensive care: Case series with therapeutic drug monitoring.
PubMed 文献 · Br J Clin Pharmacol · 2025-08-22

回顾性分析6例ICU内接受肠内营养的HIV感染者,采用治疗药物监测评估多替拉韦暴露。所有峰浓度低于3340-3670 ng/mL,8次谷浓度中6次低于最低有效浓度300 ng/mL,但仅1次低于野生型病毒PA-IC90(64 ng/mL)。通过频繁病毒载量监测和治疗药物监测,可实现治疗浓度和病毒学应答。

要点

  • ICU肠内营养患者多替拉韦峰浓度普遍低于预期范围。
  • 多数谷浓度低于最低有效浓度300 ng/mL,但多高于PA-IC90 64 ng/mL。
  • 结合频繁病毒载量监测与治疗药物监测可达到治疗浓度和病毒学应答。

核心结论

  • 重症患者多替拉韦浓度降低与肠内营养共给及危重病理生理相关。
  • 通过频繁病毒载量监测和治疗药物监测,可实现治疗浓度和病毒学应答。

研究设计与样本

  • 回顾性病例系列,来自单中心电子健康记录和数据收集。
  • 纳入6例ICU住院并接受肠内多替拉韦及治疗药物监测的HIV感染者。
  • 共获得8个治疗药物监测采样数据点。
  • 4例男性、2例女性,中位年龄34岁,中位ICU住院44.5天,中位肠内营养42.5天。

主要发现

  • 8次采样中仅3次实现了与肠内营养的适当时间间隔。
  • 所有多替拉韦峰浓度均低于3340-3670 ng/mL,无论是否与肠内营养分开给药。
  • 8次谷浓度中6次低于最低有效浓度300 ng/mL;除1例外其余谷浓度低于830-1110 ng/mL。
  • 仅1次谷浓度低于野生型病毒的PA-IC90(64 ng/mL)。

临床怎么用

  • 对ICU接受肠内营养的HIV感染者使用多替拉韦时,建议结合治疗药物监测和频繁病毒载量监测。

局限性

  • 病例数少(6例)且治疗药物监测数据点有限(8个)。
  • 需要进一步药代动力学研究以理解重症患者中多替拉韦与肠内营养共给的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

People with HIV admitted to the intensive care unit (ITU) often receive enteral nutrition via feeding tubes. Enteral feeds containing cations may interfere with dolutegravir (DTG) absorption via chelation and thus temporal spacing is recommended. This can lead to suboptimal caloric intake. We reviewed similar cases at our institution, an electronic health record and data collection, including people with HIV hospitalized in ITU with enterally administered DTG and therapeutic drug monitoring (TDM). Six cases (four males, two females, median age 34 years, median ITU admission 44.5 days, median 42.5 days on enteral nutrition) were identified with eight data points of TDM sampling. In three of eight instances, appropriate temporal spacing with enteral feeds occurred. All DTG Cmax (maximum concentrations) were lower than 3340-3670 ng/mL, regardless of temporal separation from enteral feeds. Ctrough (trough plasma concentrations) were also lower than 830-1110 ng/mL with the exception of one case. Six of eight Ctrough were lower than the DTG minimum effective concentration (MEC) of 300 ng/mL. However, only one was below PA-IC90 (in vitro protein-adjusted 90% maximal inhibitory concentration) for wildtype virus (64 ng/mL). Multiple factors such as delayed gastric emptying and changes in gastric pH are likely contributing to impaired drug absorption and reduced DTG concentrations in critically ill patients. The data on nutritional feed co-administration demonstrate that therapeutic concentrations and virological responses can be achieved with frequent viral load (VL) monitoring and TDM. Further pharmacokinetic studies on DTG in critically ill patients are warranted to better understand the impact of this co-administration.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Leung S, Temple A, Al-Shakarchi Y, et al. Dolutegravir with enteral feeds in intensive care: Case series with therapeutic drug monitoring. Br J Clin Pharmacol. 2025. PMID: 40842320. doi:10.1002/bcp.70260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。